An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.10, 2013-07, pp. : 1333-1344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip Keel Christopher Klavens Meghan Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter Svenstrup Niels Tinel Hanna Haning Helmut Bischoff Erwin

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer Bivalacqua Trinity J Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite